{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:43:07Z","timestamp":1771922587843,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clon.2020.09.005","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T22:00:58Z","timestamp":1601330458000},"page":"181-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of Concomitant Medications on Biochemical Outcome in Localised Prostate Cancer Treated with Radiotherapy and Androgen Deprivation Therapy"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6617-5522","authenticated-orcid":false,"given":"S.","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-3346","authenticated-orcid":false,"given":"S.C.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2020.09.005_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5489\/cuaj.267","article-title":"Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study","volume":"7","author":"Niraula","year":"2013","journal-title":"J\u00a0Can Urol Assoc"},{"key":"10.1016\/j.clon.2020.09.005_bib2","first-page":"1256","article-title":"Metformin use is associated with improved survival in patients with advanced prostate cancer on androgen deprivation therapy","volume":"200","author":"Richards","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clon.2020.09.005_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0161959","article-title":"Influence of statins on survival outcome in patients with metastatic castration resistant prostate cancer treated with abiraterone acetate","volume":"11","author":"Boegemann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clon.2020.09.005_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2017.00145","article-title":"Prostate cancer and aspirin use: synopsis of the proposed molecular mechanisms","volume":"8","author":"Bilani","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clon.2020.09.005_bib5","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.1158\/1078-0432.CCR-18-0420","article-title":"Metformin inhibits prostate cancer progression by targeting tumor-associated inflammatory infiltration","volume":"24","author":"Liu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2020.09.005_bib6","first-page":"105","article-title":"Metformin and prostate cancer mortality: a meta-analysis","volume":"27","author":"Stopsack","year":"2016","journal-title":"Cancer Causes Contr"},{"key":"10.1016\/j.clon.2020.09.005_bib7","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.eururo.2016.07.015","article-title":"Platinum opinion repurposing metformin as therapy for prostate cancer within the STAMPEDE trial platform on behalf of the STAMPEDE Trial Management group","volume":"70","author":"Gillessen","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2020.09.005_bib8","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/1940-6207.CAPR-17-0033","article-title":"Do aspirin and other NSAIDs confer a survival benefit in men diagnosed with prostate cancer? A pooled analysis of NIH-AARP and PLCO cohorts","volume":"10","author":"Zhou","year":"2017","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.clon.2020.09.005_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4137\/NMI.S38362","article-title":"Statin use in prostate cancer: an update","volume":"9","author":"Babcook","year":"2016","journal-title":"Nutr Metab Insights"},{"key":"10.1016\/j.clon.2020.09.005_bib10","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2012.46.7043","article-title":"Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes","volume":"31","author":"Margel","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2020.09.005_bib11","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1158\/1078-0432.CCR-13-1787","article-title":"Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response","volume":"19","author":"Zannella","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2020.09.005_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2012.12.004","article-title":"Metformin and prostate cancer: benefit for development of castration-resistant disease and prostate cancer mortality HHS public access","volume":"63","author":"Spratt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2020.09.005_bib13","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.1158\/0008-5472.CAN-10-2470","article-title":"Insulin increases de novo steroidogenesis in prostate cancer cells","volume":"71","author":"Lubik","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clon.2020.09.005_bib14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1593\/neo.11182","article-title":"Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2","volume":"13","author":"Pernicov\u00e1","year":"2011","journal-title":"Neoplasia"},{"issue":"12","key":"10.1016\/j.clon.2020.09.005_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116327","article-title":"Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies","volume":"9","author":"Yu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clon.2020.09.005_bib16","article-title":"Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis","volume":"2012","author":"Rattan","year":"2012","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.clon.2020.09.005_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature12437","article-title":"Synthetic lethal metabolic targeting of cellular senescence in cancer therapy","volume":"501","author":"D\u00f6rr","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.clon.2020.09.005_bib18","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1158\/1078-0432.CCR-10-2243","article-title":"Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth","volume":"17","author":"Rocha","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2020.09.005_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/dmrr.2645","article-title":"Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis","volume":"31","author":"Deng","year":"2015","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clon.2020.09.005_bib20","first-page":"1","article-title":"Effect of metformin on prostate cancer outcomes after radical prostatectomy","volume":"32","author":"Kaushik","year":"2014","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.clon.2020.09.005_bib21","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.urology.2010.03.059","article-title":"Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin","volume":"76","author":"Patel","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.clon.2020.09.005_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.19.01904","article-title":"Sequencing of androgen-deprivation therapy with external-beam radiotherapy in localized prostate cancer: a phase III randomized controlled trial","volume":"38","author":"Malone","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2020.09.005_bib23","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.clon.2020.09.005_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/01621459.1977.10480613","article-title":"The efficiency of Cox\u2019s likelihood function for censored data","volume":"72","author":"Efron","year":"1977","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clon.2020.09.005_bib25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A\u00a0new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Automat Contr"},{"key":"10.1016\/j.clon.2020.09.005_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/sim.4780030207","article-title":"Regression modelling strategies for improved prognostic prediction","volume":"3","author":"Harrell","year":"1984","journal-title":"Stat Med"},{"key":"10.1016\/j.clon.2020.09.005_bib27","series-title":"Modeling survival data: extending the Cox model","author":"Therneau","year":"2000"},{"key":"10.1016\/j.clon.2020.09.005_bib28","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1002\/sim.5459","article-title":"Absolute risk regression for competing risks: interpretation, link functions, and prediction","volume":"31","author":"Gerds","year":"2012","journal-title":"Stat Med"},{"key":"10.1016\/j.clon.2020.09.005_bib29","series-title":"R: a language and environment for statistical computing. Vienna","year":"2018"},{"key":"10.1016\/j.clon.2020.09.005_bib30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2020.09.005_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11934-017-0693-8","article-title":"Metformin and prostate cancer: a new role for an old drug","volume":"18","author":"Whitburn","year":"2017","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.clon.2020.09.005_bib32","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1093\/annonc\/mdr020","article-title":"Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients","volume":"22","author":"He","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2020.09.005_bib33","first-page":"329","article-title":"Type 2 diabetes and the risk of mortality among patients with prostate cancer","volume":"25","author":"Bensimon","year":"2014","journal-title":"Cancer Causes Contr"},{"key":"10.1016\/j.clon.2020.09.005_bib34","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group\/American College of Radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2020.09.005_bib35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2020.09.005_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2020.09.005_bib37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/bju.14709","article-title":"Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer","volume":"123","author":"Ranasinghe","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.clon.2020.09.005_bib38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/pmj.2005.039032","article-title":"Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors","volume":"82","author":"Daousi","year":"2006","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.clon.2020.09.005_bib39","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3892\/ol.2014.2841","article-title":"Impact of obesity upon prostate cancer-associated mortality: a meta-analysis of 17 cohort studies","volume":"9","author":"Zhang","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clon.2020.09.005_bib40","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.clon.2020.09.005_bib41","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/2159-8290.CD-12-0263","article-title":"Investigating metformin for cancer prevention and treatment: the end of the beginning","volume":"2","author":"Pollak","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clon.2020.09.005_bib42","doi-asserted-by":"crossref","first-page":"330","DOI":"10.18632\/aging.100556","article-title":"Metformin, aging and cancer","volume":"5","author":"Moiseeva","year":"2013","journal-title":"Aging"},{"key":"10.1016\/j.clon.2020.09.005_bib43","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.clon.2019.02.003","article-title":"Radiotherapy-induced senescence and its effects on responses to treatment","volume":"31","author":"Tabasso","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2020.09.005_bib44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.18632\/aging.100273","article-title":"If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice","volume":"3","author":"Anisimov","year":"2011","journal-title":"Aging"},{"key":"10.1016\/j.clon.2020.09.005_bib45","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/ijms17081339","article-title":"The role of \u03b11-adrenoceptor antagonists in the treatment of prostate and other cancers","volume":"17","author":"Batty","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clon.2020.09.005_bib46","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/iju.12156","article-title":"Reduction of prostate cancer incidence by naftopidil, an \u03b11-adrenoceptor antagonist and transforming growth factor-\u03b2 signaling inhibitor","volume":"20","author":"Yamada","year":"2013","journal-title":"Int J Urol"},{"key":"10.1016\/j.clon.2020.09.005_bib47","first-page":"2176","article-title":"Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study","volume":"178","author":"Harris","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clon.2020.09.005_bib48","first-page":"4695","article-title":"Therapeutic value of quinazoline-based compounds in prostate cancer","volume":"33","author":"Bilbro","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clon.2020.09.005_bib49","first-page":"657","article-title":"Upregulation of alpha-1 receptor gene expression in benign prostate hyperplasia patients receiving long-term alpha-blocker therapy","volume":"12","author":"Daryanto","year":"2019","journal-title":"Drug Invent Today"},{"key":"10.1016\/j.clon.2020.09.005_bib50","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1172\/JCI16293","article-title":"\u03b11-adrenergic receptors activate Ca2+-permeable cationic channels in prostate cancer epithelial cells","volume":"111","author":"Thebault","year":"2003","journal-title":"J\u00a0Clin Invest"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655520303666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655520303666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:48:18Z","timestamp":1760543298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655520303666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0936655520303666"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2020.09.005","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Concomitant Medications on Biochemical Outcome in Localised Prostate Cancer Treated with Radiotherapy and Androgen Deprivation Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2020.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}